SecBot SecBot
Biotech Drug Report Generated Aug 3, 2026

Aquipta

ABBV·AbbVie Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved (FDA approval 2021-09-28 per SecBot catalyst record); post-approval Phase 3 programs completed
Time to market
Already on the US market since September 2021 as Qulipta (atogepant); "Aquipta" is the same molecule's international/EU brand name.
Why 3/10
No hard, dated binary in the next ~12 months: atogepant was already FDA-approved (QULIPTA approval catalyst recorded 2021-09-28), its three tracked Phase 3 trials are COMPLETED with results, and no pending PDUFA/readout for this molecule appears in SecBot's FDA-catalyst data, so it lands at 3 (approved & commercializing, no pending decision, small slice of a mega-cap).
Actionable Insight NEUTRAL

ABBV's analyst tape is bullish (mean target ~$270 vs ~$251 price), but that thesis rests on the whole portfolio, not this drug.

Price Chart

Loading chart...

Executive Summary

Aquipta is the international brand name for atogepant, the once-daily oral migraine-prevention pill AbbVie sells in the US as Qulipta. The drug is approved and commercializing; its remaining tracked activity is three completed Phase 3 studies (vs topiramate, with Botox in chronic migraine, and in Japanese patients) that could support label expansion or global positioning.

How It Works

Atogepant is a small-molecule pill ("gepant" class) that blocks the CGRP pathway, a protein signaling system involved in triggering migraine attacks. Taken once daily, it is designed to prevent migraines from happening rather than treating them after onset, an oral alternative to injectable antibody preventives.

Trial Status

Three AbbVie-sponsored Phase 3 trials of atogepant are marked COMPLETED in SecBot's ClinicalTrials.gov-derived data: NCT05748483 (atogepant vs topiramate, 545 enrolled, primary completion 2025-04-28, results posted), NCT05216263 (atogepant added to onabotulinumtoxinA/Botox in chronic migraine, 75 enrolled, completed 2025-05-02, results posted), and NCT05861427 (atogepant in Japanese episodic-migraine patients, 524 enrolled, completed 2025-03-01, results posted).

The Two-Sided Case

▲ Bull Case4
Already approved: SecBot's FDA-catalyst record shows QULIPTA FDA approval on 2021-09-28 for ABBV, the biggest regulatory binary has passed and the drug is on the market.
Three AbbVie Phase 3 trials (vs topiramate, n=545; +Botox in chronic migraine; Japanese episodic migraine, n=524) are COMPLETED with results posted, data that can support label expansions and international launches.
Parent-company tape is bullish: ABBV analyst consensus shows 31 Buy/Strong-Buy vs 8 Hold/0 Sell, with a mean price target of $270.39 vs a ~$250.94 quote, and July 2026 actions included target raises to $300 (Barclays), $300 (BMO Capital), $295 (Wells Fargo).
Oral daily dosing is a convenience advantage over injectable CGRP antibody preventives, supporting the franchise's commercial ramp.
▼ Bear Case3
No pending regulatory decision or dated readout for atogepant in the next ~12 months per SecBot's FDA-catalyst data, an approved drug with no binary catalyst, and at a mega-cap like ABBV this one product is a modest slice of company value (recent ABBV FDA news concerns other drugs: Venclexta sNDA approval 2026-04-29, Epkinly sBLA approval 2026-02-04, trenibotulinumtoxinE CRL 2026-04-29).
Crowded CGRP/migraine-prevention market with branded rivals (notably Pfizer's rimegepant/Nurtec ODT and multiple injected antibodies) plus eventual oral-gepant competition and payer pressure, pricing/commercial share is the ongoing fight.
ABBV's quant snapshot is only mildly constructive (compositeScore 20, RSI-14 51.8, forward P/E 17.77) and recent insider filings are routine director RSU/SEU grants, not open-market buying signals.

Upcoming Catalysts

  • None scheduled for atogepant specifically; watch AbbVie quarterly earnings (latest 8-K filed 2026-07-31) for migraine-franchise sales trends
  • Potential label-expansion or international-launch announcements tied to the completed Phase 3 data (topiramate head-to-head, chronic-migraine add-on with Botox, Japan episodic-migraine trial)
  • Any EU/EMA or regulatory updates on the Aquipta brand (could not be verified this session due to the web-search outage)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

AbbVie Inc. 8-K ABBV ·Originating report

Sources · 5

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov4 sec.gov5 sec.gov